^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ATHENA CAR-T
i
Other names: ATHENA CAR-T, TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
EdiGene
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
24d
A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
P1, N=12, Recruiting, EdiGene Inc.
New P1 trial
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
|
cyclophosphamide • fludarabine IV • ATHENA CAR-T
8ms
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=18 --> 30
Enrollment open • Phase classification • Enrollment change • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • ATHENA CAR-T
9ms
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Chinese PLA General Hospital
New P1 trial • New P1/2 trial • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • ATHENA CAR-T
Share via
